This study investigates the molecular causes of acquired (later-developing) resistance to the drug Crizotinib in patients with non-small cell lung cancer carrying an ALK gene alteration (translocation/inversion). It included patients who progressed after responding to Crizotinib and were amenable to biopsy. It is an observational (non-phase) study and has been completed.
The summary above is a plain-language rendering of the official record. The original English title is shown for reference.
Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.
Inclusion Criteria: * ≥18 years of age * Histologically proven diagnosis of NSCLC at MSKCC Tumor positive for a translocation or inversion event involving the ALK gene locus * Clinical response to treatment with crizotinib as defined by either: Radiographic partial or complete response defined by RECIST or WHO OR: Radiographic stable disease for at least 8 weeks * Radiographic progression of disease amenable to biopsy while on treatment with crizotinib as defined by RECIST or WHO * Signed informed consent Exclusion Criteria: * Deemed by their treating physician to be medically unfit for biopsy * Women who are pregnant or breast-feeding